Abstract
During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Current Cancer Therapy Reviews
Title: Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma
Volume: 4 Issue: 2
Author(s): Nathalie Labarriere, Brigitte Dreno and Francine Jotereau
Affiliation:
Keywords: lymphocyte, TCR transgenic T cells, melanoma infiltrating lymphocytes, tumour antigen, Peripheral Blood Mononuclear Cell
Abstract: During the last few years, adoptive cellular therapy (ACT) — the isolation of antigen-specific lymphocytes, their ex vivo expansion and activation, and subsequent autologous administration — has been tested for treatment of melanoma tumours. Initial ACT used melanoma -infiltrating lymphocytes (TIL) that often contain tumour reactive lymphocytes, of diverse, mostly unknown, specificities [1, 2]. Recently, the identification of melanoma antigens [3] and the development of techniques for selection and expansion of epitope specific T cells has opened the way to the use of tumour antigen specific T cells, and importantly to immune follow up of ACT [4-9]. Despite these advances, several issues remain to address to achieve the major aims of ACT, as the rapid production of clinical grade T cells capable of eliciting a significant destruction of tumour tissue.
Export Options
About this article
Cite this article as:
Labarriere Nathalie, Dreno Brigitte and Jotereau Francine, Lymphocyte Biomarkers of Clinical Responses to Adoptive Immunotherapy of Malignant Melanoma, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310142
DOI https://dx.doi.org/10.2174/157339408784310142 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Review of Computer-Aided Models for Predicting Collagen Stability
Current Computer-Aided Drug Design New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Glycosyltransferase and Glypiation Inhibitors
Current Organic Chemistry The Complex Biology of FOXO
Current Drug Targets Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Anti-Cancer Agents in Medicinal Chemistry